Effects of anti-diabetic drugs on cardiovascular outcome in patients with diabetes mellitus

dc.contributor.advisorSztanek, Ferenc
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézethu_HU
dc.contributor.authorYamasaki, Manami
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentKáplár, Miklós
dc.contributor.opponentSomodi, Sándor
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet::Sürgősségi Orvostani Tanszékhu_HU
dc.date.accessioned2019-09-25T11:10:10Z
dc.date.available2019-09-25T11:10:10Z
dc.date.created2019-02-12
dc.description.abstractCardiovascular (CV) disease is an important complication which increases mortality and morbidity in patients with T2DM. Effective treatment is critical to lowering the subsequent risk of CV events, particularly myocadiac infarction, stroke and chronic heart failure in diabetes. Suboptimal glycemic control, obesity, hypertension, dyslipidemia, oxidative stress and autonomic dysfunction are common CV risk factors among diabetic patients. In the last three decades, several clinical trials have shown that intensive glycemic control for diabetic patients help to reduce rates of both micro- and macrovascular diseases. Since 2008, the FDA in the US requires interventional studies for CV safety for all new drugs in the treatment of diabetes. There are various ongoing mass-study for T2DM therapies for CV safety and effectiveness for other complications of diabetes.hu_HU
dc.description.correctorLB
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent43hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/273741
dc.language.isoenhu_HU
dc.subjectanti-diabetic drughu_HU
dc.subjectcardiovascular outcome
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleEffects of anti-diabetic drugs on cardiovascular outcome in patients with diabetes mellitushu_HU
Fájlok